Tocilizumab biosimilar (Fresenius kabi)

Product Name :
Tocilizumab biosimilar (Fresenius kabi)

Search keywords :
Oncostatin M

drugId :
null

Target Vo:
Interleukin-6 receptor alpha subunit

Target Vo Short Name :
IL6RA

Moa_Name:
Interleukin-6 receptor alpha subunit antagonists

First Approval Country :
EU

First Approval Date Filter:
2023

Origin Company_Name :
Merck Serono

Active Company_Name :
Fresenius Kabi Deutschland Gmbh

Active Indication_Name:
Giant Cell Arteritis

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
NeuN Antibody
KMT6/EZH2 Antibody
nNOS Antibody: nNOS Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 161 kDa, targeting to nNOS. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts